

The important regulatory roles of circRNA-encoded proteins or peptides in cancer pathogenesis (Review)

LEI ZHANG, HUIJUAN GAO, XIN LI, FEI YU and PEIFENG LI

Institute for Translational Medicine, The Affiliated Hospital of Qingdao University,
Qingdao University, Qingdao, Shandong 266021, P.R. China

Received September 26, 2023; Accepted December 13, 2023

DOI: 10.3892/ijo.2023.5607

Abstract. Circular RNAs (circRNAs) represent a class of RNA molecules characterized by their covalently closed structures. There are three types of circRNAs, namely exonic circRNAs, exon-intron circRNAs and circular intronic RNAs. To date, four distinct mechanisms have been unveiled through which circRNAs exert their functional influence, including serving as microRNA (miRNA) sponges, interacting with RNA binding proteins (RBPs), modulating parental gene transcription and acting as templates for translation. Of note, among these mechanisms, the miRNA/RBP sponge function has been the most investigated one. Recent research has uncovered the presence of various proteins or peptides encoded by circRNA. CircRNAs are translated independent of the 5' cap and 3' polyA tail, which are typical elements for linear RNA translation. Some unique elements, such as internal ribosome entry sites and N-methyladenosine modifications, facilitate the initiation of translation. These circRNA-encoded proteins or peptides participate in diverse signalling pathways and act as important regulators in carcinogenesis by influencing cell proliferation, migration, apoptosis and other key processes. Consequently, circRNA-encoded proteins or peptides have great potential as therapeutic targets for anticancer drugs. The present comprehensive review aimed to systematically summarize the current understanding of circRNA-encoded proteins or peptides and to unveil their roles in carcinogenesis.

Contents

1. Introduction
2. Characteristics of circRNAs

Correspondence to: Dr Lei Zhang or Professor Peifeng Li, Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, No. 38 Dengzhou Road, Qingdao, Shandong 266021, P.R. China
E-mail: leizhang@qdu.edu.cn
E-mail: peifli@qdu.edu.cn

Key words: circRNAs, circRNA-encoded proteins or peptides, cancers, signalling pathway, underlying mechanisms

3. CircRNA translation mechanisms
4. Identification and research methodology of circRNA-encoded proteins or peptides
5. Functional mechanisms of circRNA-encoded proteins or peptides in cancers
6. Conclusion and future perspectives

1. Introduction

Circular RNAs (circRNAs) are distinctive noncoding RNAs characterized by a covalently closed circular structure that lack the typical translation initiation elements (5' cap and 3' polyA tail) of linear RNAs (1). Originally identified in plant viruses (2), circRNAs were initially presumed to lack functional roles (3-5). Subsequently, circRNAs were found in multiple eukaryotes ranging from yeast to humans (6,7). With advances in technology and experimental methods, previous studies have confirmed the multifunctional roles of circRNAs in various physiological and pathological processes (8-10). CircRNAs are widely involved in different types of coronary artery diseases, such as myocardial infarction and angiogenesis (11,12). They also have pivotal roles in various cancer types, such as non-small cell lung cancer (1,13), gastric cancer (14,15) and glioma (16,17).

CircRNAs can function by sponging microRNAs (miRNAs) or RNA binding proteins (RBPs) and modulating parental gene expression (18). Remarkably, circRNAs can encode proteins or peptides that directly influence relevant signalling pathways (19-21). CircRNAs were first found to have protein-coding ability in viruses and prokaryotes, such as *hepatitis D virus* (22) and *Escherichia coli* (23). Subsequently, additional circRNAs that encode proteins or peptides were identified (24-26). For instance, circ-ZNF609 promotes myoblast proliferation in patients with Duchenne muscular dystrophy and can be translated into a protein in a splicing-dependent manner (27). CircMBL can be translated into a protein that may exert synaptic functions dependent on forkhead box (FOX)O activity (28). CircRNA-encoded proteins or peptides are closely associated with cancer pathogenesis (29-32). The present review offers a succinct summary of the properties and functional mechanisms of circRNAs, with a particular emphasis on the mechanisms underlying circRNA translation. Furthermore, the functions of circRNA-encoded

proteins or peptides in the pathogenesis of various cancer types are explored.

2. Characteristics of circRNAs

There are three types of circRNAs produced by backsplicing: i) Exonic circRNAs (ecRNAs) (33), ii) exon-intron circRNAs (EIciRNAs) (34) and iii) circular intronic RNAs (ciRNAs) (33). CircRNAs are produced via four different mechanisms (35). The lariat-driven circularization model, involving the activities of splice donors and acceptors, exclusively produces ecRNAs (9,36). The intron pairing-driven circularization model relies on RNA base motif pairing (e.g., Alu repeats) in introns, resulting in the generation of ecRNAs or EIciRNAs (9). In the RBP-mediated circularization model, RBPs bridge with pre-mRNAs, leading to the formation of ecRNAs or EIciRNAs. CiRNAs are produced by the binding of C-rich elements near the branch and GU-rich elements close to the 5'splice site of introns (1).

Different types of circRNAs exhibit distinct mechanisms of action (Fig. 1). EcRNAs, mainly localized in the cytoplasm (37,38), can act as miRNAs/RBP sponges to modulate downstream gene expression and encode functional proteins or peptides to influence specific pathways (1,9,39). EIciRNAs and ciRNAs, which are confined to the nucleus due to their intronic sequences (9), have roles in parental gene transcription by binding to RNA polymerase II (Pol II) (34) (Fig. 1A). CiRNAs interact with Pol II to directly enhance parental gene transcription (40). EIciRNAs form a complex with U1 small nuclear ribonucleoproteins and then interact with Pol II (34). EcRNAs containing miRNA response elements (MREs) can interact with miRNAs, exerting a 'sponge effect' that decrease miRNA levels and then upregulate the activities of miRNA targets (37) (Fig. 1B). One ecRNA may contain ≥ 1 MRE, allowing it to perform different functions. Similarly, ecRNAs can bind to RBPs resembling the sponge effect to decrease the levels of RBP and then increase the activity of RBP targets (41,42) (Fig. 1C). Unlike linear RNAs, circRNAs lack typical translation initiation elements (5' cap and 3' polyadenylated tail). However, they possess unique elements, such as N6-methyladenosine (m^6A) modifications and internal ribosome entry sites (IRESs) that facilitate their unique protein translation (19,43) (Fig. 1D).

3. CircRNA translation mechanisms

Translation initiation is the key step in protein generation. In this step, ribosomes and transfer RNAs interact with mRNAs to form an initiation complex. This intricate process involves the assembly of initiation factors into various complexes, such as the eukaryotic translation initiation factor (eIF)4E complex (comprising eIF4E, eIF4G and eIF4A) and the eIF3 complex (including eIF4G2, eIF4A and eIF4B). These complexes facilitate and ensure an accurate cap-dependent translation (44). In contrast to linear RNAs, circRNAs undergo cap-independent translation. Initiation factors bind to the IRES or m^6A to facilitate the formation of the initiation complex (45) (Fig. 1E and F).

IRES-dependent circRNA translation. The IRES is located in the 5'-untranslated region of an mRNA (46). IRES-mediated mRNA translation initiation occurs only in response to cellular stress conditions, such as hypoxia or heat shock (47). However, this IRES-dependent translation mechanism is ubiquitous across circRNAs (48). IRESs in circRNAs serve as recognition sites for initiation factors such as eIF4G and can be engaged by ribosomes to promote translation initiation (49) (Fig. 1E). Fan *et al.* (48) found multiple IRES-like short elements that were abundant in endogenous circRNAs. These IRES-like short elements could drive circRNA translation. Furthermore, numerous trans-acting factors interact with IRES-like elements.

m^6A -dependent circRNA translation. m^6A is an important regulatory modification that promotes mRNA translation (50,51). Previous studies have unveiled that even a single m^6A -modified site can trigger circRNA translation with the help of the m^6A reader YTH domain family protein 3 (YTHDF3) and eIF4G2 (29,52,53). YTHDF3 promotes the m^6A modification of eIF4G2, which subsequently recruits ribosomes to form the translation initiation complex (29,50) (Fig. 1F).

4. Identification and research methodology of circRNA-encoded proteins or peptides

Various bioinformatics tools have been developed to facilitate the identification and exploration of circRNAs with translational potential (Table I). CircBase and CircNet offer comprehensive information, including genome sequences, annotation, expression profile and possible downstream factors of circRNAs (54,55). CircCode, CircPro and CircRNADb can predict and identify circRNAs with coding potential (56-58). CircRNADb additionally provides genome sequences, IRES information and open reading frame (ORF) details (56). ORF Finder searches for possible ORFs and predicts corresponding amino acid (aa) sequences (59). BLASTp assesses the conservation of these aa sequences, providing reference information for functional research. IRESite, IRESbase, DeepM6ASeq and M6APred-EL can predict IRES/ m^6A modifications and provide evidence of their existence (60-63).

In addition to bioinformatic tools, experimental evidence is crucial to detect the translation of circRNAs. High-throughput techniques such as ribosome profiling, ribosome immunoprecipitation and ribosome affinity purification can identify circRNAs with encoding function (64). Mass spectrometry offers direct evidence through identifying specific peptides (65). Biochemical molecular techniques, including western blotting, enzyme immunoassays and dual luciferase reporting assays, enable the detection of putative peptides or proteins (66,67), screening of the targeted proteins and evaluation of IRES/ m^6A activity (29,47).

5. Functional mechanisms of circRNA-encoded proteins or peptides in cancers

Zhao *et al.* (68) reported that circRNA-encoded proteins or peptides may function as baits for functional proteins. In cancer pathogenesis, circRNA-encoded proteins or peptides exert their effects by directly interacting with various proteins, such as transcription factors, regulatory elements and signalling




Figure 1. Mechanism of action of circRNAs. There are three types of circRNAs with ecRNAs accounting for the majority. CircRNAs have different action mechanisms, including (A) regulating the transcription of parental genes, (B) sponging miRNAs, (C) interacting with RBPs and (D) encoding proteins. CircRNAs can be translated into proteins in a cap-independent manner that is mediated by (E) IRESs or (F) m⁶A modifications. CircRNA, circular RNA; miRNA, microRNA; RBP, RNA binding protein; Pol II, polymerase; ecRNA, exonic circRNA; ElciRNA, exon-intron circRNAs; ciRNA, circular intronic RNA; IRES, internal ribosome entry sites; m⁶A, N⁶-methyladenosine; YTHDF3, YTH domain family protein 3; eIF4, eukaryotic translation initiation factor 4.

components (13,16,19,69,70). Their specific roles in different cancer types are presented in Figs. 2-4 and Table II.

Glioma. Glioma, a malignant brain tumour, has a high mortality rate and is categorized into four grades (I, II, III, IV) according to the World Health Organization classification (71), with a higher grade indicating greater malignancy. Glioma frequently recurs after surgery and survival rates are markedly low. Among gliomas, glioblastoma (GBM), classified as a grade IV glioma, represents the most malignant subtype (72,73). GBM develops rapidly; it usually progresses from the initial stage to the late stage within a short period of time (only 3-6 months). CircRNAs have been demonstrated to affect glioma progression by encoding functional proteins or peptides (Fig. 2).

CircRNA F-box and WD repeat domain containing 7 (circFBXW7) generated from exons 3 and 4 of the *FBXW7* gene, was identified by deep RNA sequencing (RNA-seq) of clinical samples from patients with GBM (16). IRES-dependent translation of circFBXW7 generates a 185-aa protein named FBXW7-185aa. FBXW7-185aa overexpression induces cell cycle arrest and represses glioma cell proliferation, whereas knockdown of FBXW7-185aa exacerbates tumour symptoms. FBXW7-185aa competitively interacts with ubiquitin specific peptidase 28 (USP28) to degrade c-Myc via the ubiquitination pathway. The expression levels of circFBXW7 and FBXW7-185aa are both decreased in GBM tissues. High levels

of circFBXW7 and FBXW7-185aa are associated with a more favourable prognosis. Altogether, these observations indicate the inhibitory role of the protein encoded by circFBXW7 in glioma progression by destabilization of c-Myc (16).

Long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) is a long non-coding RNA with tumor-suppressive properties (74). Zhang *et al* (75) found a circRNA, circPINTexon2, that was generated from exon 2 of LINC-PINT. CircPINTexon2 has an active open reading frame (ORF) and contains an IRES. CircPINTexon2 can be translated to an 87-aa peptide named PINT87aa. Both PINT87aa and circPINTexon2 levels are lower in glioma tissues than in normal tissues. PINT87aa overexpression induces cell cycle arrest and inhibits tumour cell proliferation. Further experiments have revealed that circPINTexon2 acted as a tumor suppressor by encoding PINT87aa. Polymerase-associated factor complex (PAF1) participates in the recruitment of RNA Pol II and modulates the transcriptional elongation of multiple genes (76). PINT87aa directly interacts with PAF1 and suppresses the transcriptional elongation of numerous oncogenes. PINT87aa expression is negatively associated with the clinical prognosis of patients with glioma. Collectively, these results suggest that PINT87aa may function as a tumour suppressor and can serve as a therapeutic target (75).

Zhang *et al* (17) identified a circRNA with significantly decreased expression levels in GBM tissues by RNA-seq. This circRNA is generated from exons 26-29 of the *SNF2*

Table I. Databases for circRNA research.

Name	URL	Function
CircBase	http://www.circbase.org/	Collects the circRNA information of numerous species, such as humans, mice and <i>C.elegans</i>
CircNet	http://circnet.mbc.nctu.edu.tw/	Integrates the following information: Identification of new circRNAs, genome annotations of circRNAs, the expression profiles of circRNAs and the network of circRNA-miRNA-mRNA.
CircCode	https://github.com/PSSUN/CircCode	Predicts translated circRNAs.
CircPro	http://bis.zju.edu.cn/CircPro	Predicts and identifies circRNAs with coding potential.
CircRNADb	http://reprod.njmu.edu.cn/circrnadb	Summarizes IRES and ORF information of circRNAs that encode proteins; contains 32,914 human circRNAs.
ORF Finder	www.ncbi.nlm.nih.gov/gorf/gorf.html	Finds possible ORFs; deduces the translated amino acid sequence.
BLASTp	https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome	Finds and compares protein sequences.
IRESbase	http://reprod.njmu.edu.cn/cgi-bin/iresbase/index.php	Summarizes functional IRESs from various species.
RESite	http://www.iresite.org	Presents information about the structures of experimentally studied IRESs.
DeepM6ASeq	https://github.com/rreybeyb/DeepM6ASeq	Predicts the situation of single-base m ⁶ A; obtains the biological characteristics around the m6A site; visualizes the m6A site.
M6APred-EL	http://server.malab.cn/M6APred-EL/	Identifies m6A sites using ensemble learning.

CircRNA, circular RNA; miRNA, microRNA; IRES, internal ribosome entry sites; m⁶A, N6-methyladenosine; ORF, open reading frame.

histone linker PHD RING helicase (*SHPRH*) gene and is named circ-SHPRH. Circ-SHPRH has one IRES and encodes a protein known as SHPRH-146aa. Both circ-SHPRH and SHPRH-146aa exhibit reduced levels in GBM cells. SHPRH-146aa upregulation reduces tumour cell proliferation and tumorigenicity. Proliferating cell nuclear antigen (PCNA) promotes cell proliferation (77). Full-length SHPRH protein functions as an E3 ligase that ubiquitinates PCNA for degradation (77). SHPRH-146aa may stabilize the level of full-length SHPRH and then promote the degradation of PCNA, thereby decreasing cell proliferation and tumorigenicity. In general, these findings indicate that circ-SHPRH encodes a protein, namely SHPRH-146aa, which acts as an inhibitor of GBM progression by protecting SHPRH from degradation (17).

Aerobic glycolysis can promote GBM pathogenesis (78). CircRNA HEAT repeat containing 5B (circHEATR5B), derived from exons 19-33 of the *HEATR5B* gene, is expressed at low levels in GBM cells and is capable of suppressing glycolysis in these cells (70). CircHEATR5B encodes an 881-aa protein (HEATR5B-881aa) in an IRES-dependent manner. HEATR5B-881aa overexpression suppresses the glycolytic process in GBM cells, whereas HEATR5B-881aa knockdown increases glucose consumption. Consequently, HEATR5B-881aa inhibits GBM cell proliferation. CircHEATR5B cannot suppress the glycolytic process and cell proliferation in the absence of HEATR5B-881aa, suggesting an essential role for HEATR5B-881aa in mediating the inhibitory

effect of circHEATR5B on GBM cell proliferation. Jumonji-C domain-containing protein 5 (JMJD5), a protein that regulates metabolism (79), can interact with HEATR5B-881aa. HEATR5B-881aa phosphorylates JMJD5 to promote its degradation. HEATR5B-881aa upregulation decreases the JMJD5 level, and inhibits GBM cell glycolysis and proliferation. Therefore, circHEATR5B and HEATR5B-881aa function as suppressors in GBM tumorigenesis (70).

The receptor tyrosine kinase/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (AKT) pathway has a pivotal role in GBM progression (80,81). Circ-AKT3 is significantly downregulated in GBM tissues (82). Circ-AKT3 is an ecRNA originating from exons 3-7 of the *AKT3* gene. Circ-AKT3 has an ORF and an IRES that can initiate the translation of a 174-aa protein named AKT3-174aa. AKT3-174aa upregulation suppresses GBM cell proliferation, radioresistance and tumorigenicity, thus indicating its inhibitory role. The expression level of AKT3-174aa is positively associated with the overall survival rate of patients with GBM. AKT3-174aa interacts with activated (phosphorylated) 3-phosphoinositide-dependent kinase 1 and then inhibits the activation of AKT by reducing its phosphorylation at Thr308. Conclusively, these findings emphasize the antitumour role of AKT3-174aa in GBM pathogenesis by positively modulating the PI3K/AKT signalling pathway (82).

The epidermal growth factor receptor (EGFR) signalling pathway is important for GBM progression (83,84).




Figure 2. CircRNA-encoded proteins can regulate glioma pathogenesis. CircRNA-encoded proteins may act as targets of various proteins and then participate in glioma through different signalling pathways. CircRNA, circular RNA; IRES, internal ribosome entry sites; FBXW7, F-box and WD repeat domain containing 7; USP28, ubiquitin specific peptidase 28; PINT, p53-induced transcript; PAF1, polymerase-associated factor complex; SHPRH, SNF2 histone linker PHD RING helicase; PCNA, proliferating cell nuclear antigen; HEATR5B, HEAT repeat containing 5B; JMJD5, Jumonji-C domain-containing protein 5; AKT, protein kinase B; PDK1, 3-phosphoinositide-dependent kinase 1; EGFR, epidermal growth factor receptor; SMO, G protein-coupled-like receptor smoothened; PTCH1, patched homolog 1; FUS, fused in sarcoma.

Gao *et al* (85) identified a circRNA capable of encoding a protein that facilitates EGFR signalling pathway activity. By RNA-seq analysis, the authors identified circular E-cadherin (circ-E-Cad) RNA as the most upregulated circRNA. Circ-E-Cad RNA can be translated into a 254-aa protein named circRNA-encoded E-cadherin (C-E-Cad). C-E-Cad is highly expressed in cells and tissues from patients with GBM compared with control subjects. In addition, the C-E-Cad levels are negatively associated with the prognosis of patients with GBM. C-E-Cad worsens the symptoms of malignant GBM. Both C-E-Cad and circ-E-Cad levels are positively correlated with GBM cell stemness. C-E-Cad is soluble and can activate the EGFR signalling pathway by binding to the CR2 domain of EGFR, thereby promoting GBM tumorigenicity. EGFR-targeted treatments for GBM are ineffective, but the removal of C-E-Cad significantly enhances the antitumour activity of conventional anti-EGFR therapeutic strategies in GBM. Taken together, these findings indicate that C-E-Cad has an oncogenic role in GBM pathogenesis by activating the

EGFR signalling pathway, thus paving a new way for GBM treatment (85).

The Hedgehog (HH) pathway is closely related to cancer progression (86,87). The G protein-coupled-like receptor smoothened (SMO) and glioma-associated oncoprotein Gli1 are key components of HH signalling (88). Wu *et al* (21) reported that circSMO, generated from exons 3-6 of the *SMO* gene, was highly expressed in GBM tissues. CircSMO contains an IRES and may be translated into a 193-aa protein termed SMO-193a.a. High SMO-193a.a levels may indicate poor prognosis. SMO-193a.a knockdown inhibits the self-renewal and decreases the proliferation and tumorigenicity of brain cancer stem cells, suggesting an oncogenic role of SMO-193a.a. SMO-193a.a knockdown also obviously reduces HH signalling activity. SMO-193a.a directly interacts with SMO to activate it. SMO-193a.a participates in the activation of SMO induced by sonic HH (Shh) through promoting SMO-mediated cholesterol modification and rescuing SMO from inhibition by patched homolog 1, a patched family transmembrane receptor.




Figure 3. Roles of circRNA-encoded proteins in (A) TNBC, (B) gastric cancer and (C) colon cancer. CircRNA, circular RNA; IRES, internal ribosome entry sites; TNBC, triple-negative breast cancer; m⁶A, N⁶-methyladenosine; EMT, epithelial to mesenchymal transition; ubi, ubiquitin; MYH9, myosin 9; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; APC, adenomatous polyposis coli; DIDO1, the death-inducer obliterator 1; PARP1, poly ADP-ribose polymerase 1; PRDX2, peroxiredoxin-2; MAPK, mitogen-activated protein kinase; MEK1, mitogen-activated protein kinase kinases 1; PPP1R12A, protein phosphatase 1, regulatory subunit 12a; YAP1, Yes-associated protein 1; FNDC3B, fibronectin type III domain-containing protein 3B; EMT, epithelial-mesenchymal transition; FBP1, fructose-1,6-bisphosphatase 1; MKK6, MAPK kinase 6; FOXC1, forkhead box C1 protein; U2AF2, U2 auxiliary factor; PLCE1, phospholipase C epsilon 1; RPS3, ribosomal protein S3; HSP90 α , heat-shock protein 90 α .

Importantly, SMO-193a.a is a direct target of fused in sarcoma (FUS), which is a direct transcriptional target of Gli1. Taken together, these findings demonstrate that SMO-193a.a functions as an oncogenic protein and promotes GBM through the HH signalling axis-Shh/Gli1/FUS/SMO-193a.a/SMO (21).

Triple-negative breast cancer (TNBC). Breast carcinomas (BC) are heterogeneous tumours. TNBC is the subtype of BC with the poorest prognosis (89). Studies have shown that circRNAs may be translated into important proteins or peptides that influence TNBC progression (31,66,90) (Fig. 3A).

CircFBXW7 can encode a protein with 185 aa (FBXW7-185aa) via its IRES (16). FBXW7-185aa has been found to suppress gliomagenesis (16). Ye *et al* (31) explored the role of circFBXW7 in TNBC. The levels of circFBXW7 were reduced in patients with TNBC, while overexpression of circFBXW7 inhibited tumour progression. Furthermore, FBXW7-185aa may be produced in TNBC cells. FBXW7-185aa overexpression obviously hindered TNBC cell proliferation and migration (31). FBXW7-185aa upregulation may reverse the oncogenic effect of circFBXW7 downregulation. FBXW7-185aa promoted FBXW7 expression and facilitated c-Myc degradation via ubiquitination. USP28 had the opposite effect to that of FBXW7-185aa. Overall, these findings indicate that circFBXW7 and FBXW7-185aa can suppress TNBC development (31).

Li *et al* (66) identified a circRNA, circ-EIF6, whose expression was associated with poor prognosis in patients with TNBC. Circ-EIF6 can promote TNBC cell proliferation, migration and invasion. Circ-EIF6 encodes a novel peptide with 224 aa (EIF6-224aa) in an IRES-dependent manner. Both TNBC tissues and cell lines exhibit endogenous expression of

EIF6-224aa. The oncogenic function of circ-EIF6 is dependent on EIF6-224aa (66). Myosin-9 (MYH9), known for its role in promoting BC pathogenesis, is a direct target of EIF6-224aa. EIF6-224aa participates in the ubiquitin-proteasome pathway, reducing the degradation of MYH9. Upregulation of MYH9 stimulates the Wnt/ β -catenin pathway, thereby promoting tumorigenesis. Altogether, these observations show that circ-EIF6 has an oncogenic role in TNBC by encoding EIF6-224aa, which enhances the activity of the MYH9/Wnt/ β -catenin signalling pathway (66).

Human epidermal growth factor receptor 2 (HER2) is an important target for TNBC treatment. Li *et al* (90) identified a circular RNA named circ-HER2, which is produced from exons 3-7 of the *HER2* gene by backsplicing. Circ-HER2 has an ORF that can be translated into a 103-aa protein driven by an IRES. This protein is denoted as HER2-103. Circ-HER2 and HER2-103 are expressed in ~30% of TNBC tissues and their levels are negatively correlated with prognostic efficacy. HER2-103 knockout suppresses TNBC cell proliferation, invasion and tumorigenicity. HER2-103 can directly interact with EGFR and HER3 to promote the formation of EGFR/EGFR homodimers or EGFR/HER3 heterodimers. This binding subsequently activates downstream signalling cascades to promote tumorigenesis. The majority of the HER2-103 sequences are identical to the HER2 CR1 domain, which can be targeted by pertuzumab, an antibody against HER2. Addition of pertuzumab reverses the tumour-promoting effect of HER2-103 overexpression, suggesting that HER2-103 is a possible clinical target for TNBC treatment (90).

Gastric cancer (GC). GC is a common malignancy with high morbidity and mortality. The pathological progression of GC




Figure 4. Roles of circRNA-encoded proteins in (A) NSCLC, (B) liver cancer, (C) endometrial cancer, (D) multiple myeloma, (E) neuroblastoma and (F) ESCC. NSCLC, non-small cell lung cancer; circRNA, circular RNA; IRES, internal ribosome entry sites; m6A, N6-methyladenosine; GSK3 β , glycogen synthase kinase 3 β ; ASK1, apoptosis signal-regulating kinase 1; MAP3K4, mitogen-activated protein kinase kinase kinase 4; AIF, apoptosis-inducing factor; ARNT, aryl hydrocarbon receptor nuclear translocator; VEGF, vascular endothelial growth factor; CHEK1, checkpoint kinase 1; CUX1, CUT-like homeobox 1; ZRF1, Zuo1in-related factor 1; BRD4, bromodomain protein 4; UBE4B, ubiquitination factor E4B; ERK, extracellular signal-regulated kinase.

is notably slow, often making early detection challenging (91). Therefore, patients with GC are frequently diagnosed at advanced stages, implying a generally poor prognosis. Consequently, the exploration of effective therapeutic targets and regulators is of great importance. Recent studies have shown that circRNAs can encode functional proteins to modulate GC pathogenesis (15,20,42) (Fig. 3B).

Adenomatous polyposis coli (APC)/AXIN is a regulatory complex that inhibits the Wnt/ β -catenin signalling pathway (92). AXIN dysfunction results in the abnormal accumulation of β -catenin (92). CircAXIN1 is derived from exon 2 of the *AXIN* gene (20). Peng *et al* (20) found upregulated circAXIN1 expression in GC tissues. CircAXIN1 overexpression promotes GC cell proliferation, migration and invasion, whereas circAXIN1 downregulation suppresses gastric tumorigenesis. CircAXIN1 is able to encode a 295-aa protein (AXIN1-295aa) in a process dependent on an IRES. AXIN1-295aa directly interacts with the APC protein to block the interaction between AXIN1 and APC, thus abolishing the suppressive effect of the AXIN/APC complex on the Wnt/ β -catenin pathway. This leads to the activation of the Wnt/ β -catenin pathway, which, in turn, promotes gastric tumorigenesis. Therefore, circAXIN1 may promote gastric tumorigenesis via AXIN1-295aa (20).

The death-inducer obliterator 1 (*DIDO1*) gene has a role in apoptosis and regulates tumour development (93). CircDIDO1 is derived from exons 2-6 of the *DIDO1* gene. CircDIDO1 levels are decreased in GC tissues (43). A low circDIDO1 level indicates worse tumour symptoms and poor prognosis, indicating an oncogenic role of circDIDO1. CircDIDO1 can be translated into a 529-aa protein (DIDO1-529aa) with the help of m⁶A modification. DIDO1-529aa upregulation suppresses GC cell proliferation, migration and invasion. Co-immunoprecipitation

assays revealed an interaction between DIDO1-529aa and poly ADP-ribose polymerase 1 (PARP1), which is an apoptosis inhibitor. DIDO1-529aa upregulation reduces the PARP1 level, ultimately resulting in apoptosis. In addition, circDIDO1 may facilitate GC progression by inducing the ubiquitin-mediated degradation of peroxiredoxin-2 (PRDX2), a protein that promotes tumorigenesis (94,95). Taken together, the findings indicate that circDIDO1 can inhibit gastric tumorigenesis by encoding the DIDO1-529aa protein, which promotes PRDX2 degradation (43).

The mitogen-activated protein kinase (MAPK) signalling pathway is a classical signal transduction pathway that participates in cell proliferation, differentiation, metastasis and other processes (96). CircMAPK1, generated from exons 2-4 of the *MAPK1* gene, is downregulated in GC tissues and cell lines (15). A low circMAPK1 level suggests poor survival in patients with GC. CircMAPK1 may suppress GC cell proliferation and invasion *in vivo* and *in vitro*. With an ORF and an IRES, circMAPK1 can be translated into a 109-aa protein, MAPK1-109aa. MAPK1-109aa competitively interacts with MAPK kinase 1, an upstream kinase in the MAPK signaling pathway, and then inhibits MAPK1 phosphorylation, leading to the inactivation of MAPK1 and the downstream signalling pathway. Altogether, these observations indicate that circMAPK1 has an antitumour role in GC progression via its encoded protein MAPK1-109aa (15).

Colorectal cancer (CRC). CRC is a solid malignancy originating in the large intestine (97). Despite advances in therapeutic techniques, the metastasis and recurrence rates of CRC remain high. CircRNAs and the proteins they encode have emerged as crucial regulators of CRC pathogenesis, offering potential insight into prognosis (26,39,69) (Fig. 3C).

Table II. Functional roles of circRNA-encoded proteins in cancers.

Cancer type	Protein	Effect	Expression	Possible mechanisms	(Refs.)
Glioma	FBXW7-185aa	Suppression	Downregulated	Promotes cMyc degradation by ubiquitination	(16)
	PINT87aa	Suppression	Downregulated	Suppresses the transcriptional elongation of oncogenes	(75)
	SHPRH-146aa	Suppression	Downregulated	Promotes PCNA degradation by ubiquitination	(17)
	HEATR5B-881aa	Suppression	Downregulated	Promotes JMJD5 degradation by phosphorylation	(70)
	AKT3-174aa	Suppression	Downregulated	Suppresses the PI3K/AKT signalling pathway	(82)
	C-E-Cad	Promotion	Upregulated	Promotes EGFR signalling activation	(85)
	SMO-193aa	Promotion	Upregulated	Promotes HH signalling activation	(21)
Triple-negative breast cancer	FBXW7-185aa	Suppression	Downregulated	Promotes FBXW7 expression and c-Myc degradation	(31)
	EIF6-224aa	Promotion	Upregulated	Promotes Wnt/ β -catenin pathway activation	(66)
	HER2-103	Promotion	Upregulated	Promotes activation of the EGFR pathway	(90)
Gastric cancer	AXIN1-295aa	Promotion	Upregulated	Promotes Wnt/ β -catenin pathway activation	(20)
	DIDO1-529aa	Suppression	Downregulated	Promotes apoptosis and inhibits PRDX2 activity	(43)
	MAPK1-109aa	Suppression	Downregulated	Inhibits MAPK1 phosphorylation, to inactivate the MAPK1 pathway	(15)
Colorectal cancer	circPPP1R12A-73aa	Promotion	Upregulated	Promotes activation of the Hippo-YAP signalling pathway	(25)
	circFNDC3B-218aa	Suppression	Downregulated	Suppresses the Snail-FBP-EMT axis	(26)
	circMAPK14-175aa	Suppression	Downregulated	Promotes the degradation of FOXC1 through ubiquitination	(69)
	circPLCE1-411	Suppression	Downregulated	Suppresses NF- κ B signalling	(39)
Non-small-cell lung cancer	circ β -catenin-370aa	Promotion	Upregulated	Promotes the β -catenin signalling pathway	(13)
	ASK1-272a	Suppression	Downregulated	Promotes the ASK1 signalling pathway	(108)
Liver cancer	CircMAP3K4-455aa	Promotion	Upregulated	Suppresses nuclear distribution of AIF	(110)
	circ β -catenin-370aa	Promotion	Upregulated	Promotes the β -catenin signalling pathway	(111)
Endometrial cancer	CORO1C-47aa	Suppression	Downregulated	Suppresses VEGF expression	(19)
Multiple myeloma	circCHEK1_246aa	Promotion	Upregulated	Promotes chromosomal instability	(32)
Neuroblastoma	p113	Promotion	Upregulated	Promotes the p113/ZRF1/BRD4 pathway	(118)
Esophageal squamous cell carcinoma	circUBE4B-173aa	Promotion	Upregulated	Activates the MAPK/ERK pathway	(122)

CircRNA, circular RNA; HH, hedgehog; YAP, Yes-associated protein; FBXW7, F-box and WD repeat domain containing 7; PCNA, proliferating cell nuclear antigen; JMJD5, Jumonji-C domain-containing protein 5; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; PDK1, 3-phosphoinositide-dependent kinase 1; EGFR, epidermal growth factor receptor; HH, Hedgehog; HER2, human epidermal growth factor receptor 2; PRDX2, peroxiredoxin-2; MAPK, mitogen-activated protein kinase; YAP1, Yes-associated protein 1; EMT, epithelial-mesenchymal transition; FBP1, fructose-1,6-bisphosphatase 1; FOXC1, forkhead box C1 protein; ASK1, apoptosis signal-regulating kinase 1; AIF, apoptosis-inducing factor; VEGF, vascular endothelial growth factor; ZRF1, zuotin-related factor 1; BRD4, bromodomain protein 4; ERK, extracellular signal-regulated kinase.

Zheng *et al* (25) carried out a circRNA microarray analysis using CRC and control tissues, and identified hsa_circ_0000423 as the most upregulated circRNA. Hsa_circ_0000423 is derived from exons 24 and 25 of the protein phosphatase 1, regulatory subunit 12a (*PPP1R12A*) gene, and is also named circPPP1R12A. CircPPP1R12A expression is significantly increased in CRC tissues and cell lines. CircPPP1R12A encodes a 73-aa protein, named circPPP1R12A-73aa. CircPPP1R12A-73aa enhances CRC cell proliferation and metastasis. Yes-associated protein 1 (YAP1), a transcriptional activator of the Hippo-YAP signalling pathway, is essential for cancer cell proliferation and metastasis (98). CircPPP1R12A-73aa can interact with YAP1 and other proteins in the Hippo-YAP signalling pathway. YAP1 knockdown attenuates the oncogenic effect of circPPP1R12A-73aa on CRC cells, suggesting that circPPP1R12A-73aa promotes CRC tumorigenesis by activating the Hippo-YAP signalling pathway (25).

Fibronectin type III domain-containing protein 3B (FNDC3B) is associated with cell migration (99). CircFNDC3B, generated from exons 5 and 6 of the *FNDC3B* gene, has been implicated in various cancer types (14,100). CircFNDC3B can encode a protein (14), although the specific functions of this protein are still unknown. Pan *et al* (26) reported the role of circFNDC3B as a translation template in CRC development. CircFNDC3B is downregulated in CRC tissues and cell lines. Lower levels of circFNDC3B are associated with poor overall survival. Overexpression of circFNDC3B suppresses CRC cell proliferation, migration and invasion. CircFNDC3B may be translated into a 218-aa protein, called circFNDC3B-218aa, which exerts inhibitory effects on CRC cell proliferation, invasion and migration. Snail is a transcription factor known to induce epithelial-mesenchymal transition (EMT) by reducing fructose-1,6-bisphosphatase 1 (FBP1) expression (24,101). Mechanistic exploration has shown that circFNDC3B-218aa can suppress the expression of the Snail protein, resulting in FBP1 upregulation and EMT inhibition in CRC cells. Overall, these observations suggest that circFNDC3B-218aa may have a tumour-suppressive role in CRC pathogenesis through the Snail-FBP-EMT axis (26).

MAPK14, a key member of the MAPK family, has pivotal roles in CRC (102). CircMAPK14 is generated from exons 4-10 of the *MAPK14* gene. CircMAPK14 levels are markedly reduced in CRC samples (69). Overexpression of circMAPK14 inhibits CRC cell proliferation and migration. CircMAPK14 contains an IRES that drives the translation of a 175-aa protein (circMAPK14-175aa). CircMAPK-175aa abolishes tumorigenicity and blocks the metastasis of CRC cells. CircMAPK14-175aa can interact with MAPK kinase 6 to reduce the nuclear translocation of MAPK14, thus promoting the degradation of FOXC1 protein through ubiquitination. FOXC1 suppresses the transcription of U2 auxiliary factor (U2AF2). U2AF2 can bind to *MAPK14* introns and promote circMAPK14 expression. Thus, a positive feedback loop is formed: CircMAPK14-175aa inhibits FOXC1 activity to upregulate U2AF2. In turn, higher U2AF2 levels promote the formation of circMAPK14 and the translation of circMAPK14-175aa. In summary, these results indicate that circMAPK14 and circMAPK14-175aa suppress CRC progression by regulating FOXC1 and U2AF2 activity (69).

Through RNA-seq analysis, Liang *et al* (39) found that the levels of circRNA phospholipase C epsilon 1 (PLCE1)

were significantly lower in CRC tissues than in normal control tissues. Lower circPLCE1 levels are positively associated with poor overall survival in patients with CRC, indicating its potential as a prognostic biomarker. CircPLCE1 overexpression suppresses the proliferation and migration of CRC cells. CircPLCE1 is generated from exon 2 of the *PLCE1* gene and encodes a 411-aa protein whose translation is driven by an IRES. The expression levels of circPLCE1-411 are decreased in most CRC tissues. CircPLCE1-411 can regulate the NF- κ B signalling pathway, which is known to promote CRC development and progression (103,104). Ribosomal protein S3 (RPS3) is the most important regulator of the NF- κ B pathway. Heat-shock protein (HSP)90 α interacts with RPS3 to form the RPS3/HSP90 α complex, which inhibits the ubiquitin-dependent degradation of RPS3 (105,106). CircPLCE1-411 binds to HSP90 α to mediate the dissociation of the HSP90 α /RPS3 complex. The released RPS3 is degraded by ubiquitination. Subsequently, the NF- κ B signalling pathway is inhibited, leading to the suppression of colorectal tumorigenesis. Therefore, circPLCE1 serves as a tumour suppressor by encoding the protein circPLCE1-411 to suppress the NF- κ B signalling pathway (39).

Lung cancer. Non-small cell lung cancer (NSCLC) is the most prevalent and malignant type of lung cancer, with high mortality and morbidity due to its high metastasis and recurrence rates (107). CircRNAs are important regulators of NSCLC pathogenesis (1). Recent studies have revealed that the proteins or peptides encoded by circRNAs also participate in NSCLC progression (13,108) (Fig. 4A).

Zhao *et al* (13) found that circ β -catenin was involved in NSCLC formation. Circ β -catenin expression is upregulated in NSCLC tissues. Circ β -catenin overexpression promotes NSCLC cell proliferation, migration and invasion. The oncogenic effect of circ β -catenin in NSCLC is mediated through the activation of the Wnt/ β -catenin pathway. Circ β -catenin encodes a 370-aa peptide (circ β -catenin-370aa) driven by an IRES. Circ β -catenin-370aa can bind to glycogen synthase kinase (GSK)3 β to inhibit the GSK3 β -mediated phosphorylation of β -catenin, thus stimulating the Wnt/ β -catenin pathway. Therefore, circ β -catenin promotes NSCLC by encoding a peptide that increases the activity of the Wnt/ β -catenin signalling pathway (13).

Lung adenocarcinoma (LUAD) is a major histological type of NSCLC (30). Apoptosis signal-regulating kinase 1 (ASK1) induces apoptosis and regulates the stress response by activating the c-Jun N-terminal kinase and p38 signalling pathways (109). Gefitinib is a clinical therapeutic agent used to treat LUAD, but resistance to this drug is an important clinical challenge. CircASK1 and its encoded protein, ASK1-272aa, can participate in acquired gefitinib resistance in LUAD (108). CircASK1 is derived from exons 2-7 of the *ASK1* gene and is markedly downregulated in gefitinib-resistant LUAD cells. Decreased circASK1 expression contributes to gefitinib resistance in LUAD cells. CircASK1 encodes a 272-aa protein, ASK1-272aa, whose sequence is similar to that of the ASK1 protein. ASK1-272aa levels are reduced in gefitinib-resistant LUAD cells. ASK1-272aa upregulation enhances the gefitinib sensitivity of LUAD cells. ASK1-272aa competitively binds to Akt1 to release ASK1 from phosphorylation-mediated inactivation. Activated ASK1 enhances ASK1-mediated apoptosis in LUAD cells and increases the sensitivity of LUAD cells to

gefitinib (108). In general, these observations demonstrate that circASK1 can decrease gefitinib resistance in LUAD cells via ASK1-272aa (108).

Liver cancer. Liver cancer is a devastating cancer type with a poor prognosis. The lack of techniques for early diagnosis, the limited therapeutic options and chemotherapeutic resistance make the treatment of liver cancer difficult. CircRNAs and their encoded proteins or peptides have emerged as important regulators in liver cancer progression (110,111) (Fig. 4B).

Hepatocellular carcinoma (HCC) is a type of primary liver cancer. CircMAP3K4, generated from exon 3 of the MAPK kinase kinase 4 (*MAP3K4*) gene, is upregulated in HCC (110). Higher levels of circMAP3K4 indicate poor overall survival. CircMAP3K4 can be translated into a 455-aa peptide, circMAP3K4-455aa via m⁶A modification. CircMAP3K4-455aa promotes HCC development *in vivo* and *in vitro*. Apoptosis-inducing factor (AIF), a regulator of cell survival and death, can interact with circMAP3K4-455aa. Such interaction reduces the nuclear distribution of AIF and suppresses cisplatin-induced HCC cell apoptosis. Therefore, circMAP3K4-455aa enhances HCC progression by influencing AIF activity (110).

Circ β -catenin and its encoded protein circ β -catenin-370aa can promote the progression of liver cancer (111). Circ β -catenin is significantly upregulated in liver cancer tissues. Circ β -catenin-370aa interacts with GSK3 β to abolish the GSK3 β -mediated degradation of β -catenin, thereby promoting Wnt/ β -catenin signalling. Activation of the Wnt/ β -catenin signalling pathway enhances liver cancer progression (111).

Endometrial cancer (EC). EC is a common malignant tumour in women that accounts for 1-2% of cancer-associated mortalities (107,112). Li *et al* (19) conducted deep RNA-seq on human EC tissue samples and identified a circRNA (circ-0000437) that was involved in EC progression (Fig. 4C). Circ-0000437 is significantly downregulated in EC samples and does not function as a miRNA sponge. Circ-0000437 encodes a 47-aa peptide (named CORO1C-47aa) in the presence of an IRES. CORO1C-47aa overexpression suppresses angiogenesis in EC through inhibiting the proliferation, migration and differentiation of endothelial cells. CORO1C-47aa interacts with the aryl hydrocarbon receptor nuclear translocator (ARNT) protein, which is related to hypoxia (113). CORO1C-47aa competes with transforming acidic coiled-coil-containing protein 3, a co-activator of the vascular endothelial growth factor (VEGF) promoter, for binding to ARNT to suppress VEGF activation, thereby inhibiting angiogenesis in EC. Thus, CORO1C-47aa has an antitumour role in EC pathogenesis by decreasing VEGF expression (19).

Multiple myeloma (MM). MM originates in the bone marrow. MM is different from solid tumours, as it is a plasma cell malignancy. MM is difficult to cure and the mortality rate is markedly high (114). Checkpoint kinase 1 (CHEK1) facilitates MM development (115,116). CHEK1 overexpression promotes MM cell proliferation and macrophage-osteoclast differentiation, and enhances the drug resistance of MM cells, thus having an oncogenic role (32). CircCHEK1 is derived from the

CHEK1 gene and can be translated into a functional protein called circCHEK1_246aa in an IRES-dependent manner (Fig. 4D). Chromosomal instability is related to cell proliferation. CircCHEK1_246aa overexpression in MM cells results in chromosomal instability, thereby promoting MM cell proliferation. Furthermore, macrophage-osteoclast differentiation is enhanced. Taken together, these findings indicate that CHEK1 and circCHEK1_246aa are promising therapeutic targets in MM (32).

Neuroblastoma (NB). NB is a sympathetic nervous system tumour that originates at the neural crest and is one of the most malignant life-threatening tumours in children. CUT-like homeobox 1 (*CUX1*) is a homeodomain transcription factor that regulates the pathogenesis of numerous tumours (117). *CUX1* can produce a circRNA, termed ecirc*CUX1* (118) (Fig. 4E). In an IRES-mediated manner, ecirc*CUX1* is translated into a 113-aa protein (p113) that is upregulated in NB samples. p113 facilitates lipid metabolism, increases mitochondrial activity and promotes NB cell proliferation, migration and metastasis. Ecirc*CUX1* exacerbates NB cell tumour symptoms via p113. p113 functions by directly binding to Zuotin-related factor 1 (*ZRF1*) and bromodomain protein 4 (*BRD4*) to form a transcriptional regulatory complex. The activity of the p113/*ZRF1*/*BRD4* complex increases the levels of lipid metabolism-related proteins to induce lipid metabolic reprogramming and mitochondrial complex I activity, thereby increasing the tumorigenesis and aggressiveness of NB cells. Disassociation of the p113-*ZRF1* complex attenuates NB pathogenesis. High levels of p113, *ZRF1* and *BRD4* indicate poor overall survival in patients with NB. Overall, these results indicate that the ecirc*CUX1*-encoded protein has an oncogenic role in NB through the formation of the p113/*ZRF1*/*BRD4* complex (118).

Esophageal squamous cell carcinoma (ESCC). ESCC is one of the invasive malignant cancers with the highest mortality rate (36,119). The 5-year survival rate of patients with ESCC is <50%. Understanding the mechanisms underlying ESCC development and exploring potential biological predictors are of great importance. Emerging evidence implicates circRNAs in ESCC pathogenesis (120,121). In a recent study, Lyu *et al* (122) conducted a microarray analysis and identified a circRNA with protein coding potential, named circUBE4B (Fig. 4F). CircUBE4B is formed from exons 6-9 of the ubiquitination factor E4B (*UBE4B*) gene. CircUBE4B is upregulated in ESCC tissues. High expression of circUBE4B is negatively associated with the overall survival rate of patients with ESCC. CircUBE4B contains an IRES that facilitates the translation of a novel 173-aa protein (circUBE4B-173aa), whose elevated expression in ESCC indicates poor prognosis. Overexpression of circUBE4B-173aa promotes the proliferation of ESCC cells. CircUBE4B-173aa is involved in the MAPK pathway, which functions in tumorigenesis (123). Further investigations reveal that circUBE4B-173aa can bind to MAPK1 to phosphorylate MAPK1, leading to the subsequent activation of the MAPK/extracellular signal-regulated kinase (ERK) pathway. *In vivo* experiments also demonstrate that circUBE4B-173aa overexpression enhances tumor growth. Collectively, all of

these findings indicate that circUBE4B-encoded protein promotes ESCC by interacting with MAPK1 to activate the MAPK/ERK pathway (122).

6. Conclusion and future perspectives

The characteristics of circRNAs, such as their unique conformation and stability, have attracted numerous researchers to develop technologies based on circRNAs (124,125). The high stability and specific expression of circRNAs make them promising candidate diagnostic and prognostic biomarkers. CircRNAs can be employed in the development of circRNA-based aptamers or sensors to modulate various intracellular pathways (126). CircRNAs containing IRESs/m⁶A modifications are translatable, implying their potential as expression vectors to initiate the production of diverse proteins. There have been some patents that confirm the roles of circRNAs as effective vectors/carriers for vaccines. In comparison to linear RNA (mRNA) vaccines, circRNA vaccines exhibit higher stability and reduced susceptibility to degradation. Of note, during the COVID-19 pandemic, scientists developed circRNA vaccines aimed at enabling enhanced and more enduring antigen production (127).

CircRNA-encoded proteins/peptides hold significant potential for extensive clinical applications in cancer, such as early diagnosis, drug development, prognosis and treatment. Based on the antigen-antibody interaction principle, a rapid test strip method has been developed for early diagnosis, including early pregnancy, COVID-19 detection and H1N1 detection strips. This method offers non-invasive, fast and convenient (only several drops of urine or nasal mucus are needed) diagnostic options, facilitating a quick preliminary diagnosis at home. The prospect of constructing distinct circRNA-encoded protein/peptide strips for diagnosing various cancer types seems feasible. In the realm of cancer therapy, precise treatment and targeting are crucial. The limited number of effective target drugs is mainly due to low target specificity, which highlights the need for more precise approaches. Compared with nucleotide targets, protein targets are more specific. Developing precision antitumour drugs targeting proteins or peptides translated from circRNAs may yield highly selective and minimally toxic therapeutic effects. Despite their potential, challenges must be addressed before clinical implementation.

First, the rapid degradation of multiple circRNA-encoded proteins or peptides results in low abundance (48). This adds to the difficulty of their clinical application. Second, the understanding of circRNA translation mechanisms is still insufficient. Many underlying mechanisms are unclear and need further exploration. Third, there is a lack of a uniform naming method for proteins or peptides translated from circRNAs, making research findings across different laboratories confusing. Therefore, more efforts should be made to overcome these limitations. Future studies should provide new insight and ideas for clinical applications.

In summary, circRNA-encoded proteins or peptides have crucial roles in numerous signalling pathways and are thus important factors in cancer pathogenesis. The aforementioned findings open up new avenues for cancer diagnosis and therapeutic strategies.

Acknowledgements

Not applicable.

Funding

This work was funded by the Natural Science Foundation of Shandong Province, China (grant no. ZR2020QH016) and Integrated Project of Major Research Plan of the National Natural Science Foundation of China (grant no. 92249303).

Availability of data and materials

Not applicable.

Authors' contributions

LZ drafted the manuscript. HG and XL edited the manuscript. FY revised the manuscript. LZ and PL conceived the idea of the review and performed the final proofreading. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Liu Y, Ao X, Yu W, Zhang Y and Wang J: Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer. *Mol Ther Nucleic Acids* 27: 50-72, 2021.
- Kolakofsky D: Isolation and characterization of Sendai virus DI-RNAs. *Cell* 8: 547-555, 1976.
- Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, Goodfellow P and Lovell-Badge R: Circular transcripts of the testis-determining gene Sry in adult mouse testis. *Cell* 73: 1019-1030, 1993.
- Cocquerelle C, Daubersies P, Majerus MA, Kerckaert JP and Bailleul B: Splicing with inverted order of exons occurs proximal to large introns. *EMBO J* 11: 1095-1098, 1992.
- Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW and Vogelstein B: Scrambled exons. *Cell* 64: 607-613, 1991.
- Schroeder R, Breitenbach M and Schweyen RJ: Mitochondrial circular RNAs are absent in sporulating cells of *Saccharomyces cerevisiae*. *Nucleic Acids Res* 11: 1735-1746, 1983.
- Cocquerelle C, Mascrez B, Hetuin D and Bailleul B: Mis-splicing yields circular RNA molecules. *FASEB J* 7: 155-160, 1993.
- Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C, Zhang J, Wang J and Liu Y: Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. *Front Oncol* 12: 951864, 2022.
- Zhang L, Zhang Y, Yu F, Li X, Gao H and Li P: The circRNA-miRNA/RBP regulatory network in myocardial infarction. *Front Pharmacol* 13: 941123, 2022.
- Wang M, Yu F, Li P and Wang K: Emerging Function and clinical significance of Exosomal circRNAs in cancer. *Mol Ther Nucleic Acids* 21: 367-383, 2020.

11. Zhang L, Zhang Y, Wang Y, Zhao Y, Ding H and Li P: Circular RNAs: Functions and clinical significance in cardiovascular disease. *Front Cell Dev Biol* 8: 584051, 2020.
12. Ye XM, Hang YW, Lu Y, Li D, Shen F, Guan P, Dong J, Shi L and Hu W: CircRNA circ-NNT mediates myocardial ischemia/reperfusion injury through activating pyroptosis by sponging miR-33a-5p and regulating USP46 expression. *Cell Death Discov* 7: 370, 2021.
13. Zhao W, Zhang Y and Zhu Y: Circular RNA circbeta-catenin aggravates the malignant phenotype of non-small-cell lung cancer via encoding a peptide. *J Clin Lab Anal* 35: e23900, 2021.
14. Hong YL, Qin HF, Li Y, Zhang Y, Zhuang X, Liu L, Lu K, Li L, Deng X, Liu F, *et al*: FNDC3B circular RNA promotes the migration and invasion of gastric cancer cells via the regulation of E-cadherin and CD44 expression. *J Cell Physiol* 234: 19895-19910, 2019.
15. Jiang T, Xia Y, Lv J, Li B, Li Y, Wang S, Xuan Z, Xie L, Qiu S, He Z, *et al*: A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling. *Mol Cancer* 20: 66, 2021.
16. Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, Huang N, Yang X, Zhao K, Zhou H, *et al*: Novel Role of FBXW7 Circular RNA in repressing glioma tumorigenesis. *J Natl Cancer Inst* 110: 304-315, 2018.
17. Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, Chen W, Gao X, Zhao K, Zhou H, *et al*: A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. *Oncogene* 37: 1805-1814, 2018.
18. Wang M, Yu F, Zhang Y, Zhang L, Chang W and Wang K: The Emerging roles of circular RNAs in the chemoresistance of gastrointestinal cancer. *Front Cell Dev Biol* 10: 821609, 2022.
19. Li F, Cai Y, Deng S, Yang L, Liu N, Chang X, Jing L, Zhou Y and Li H: A peptide COROIC-47aa encoded by the circular noncoding RNA circ-0000437 functions as a negative regulator in endometrium tumor angiogenesis. *J Biol Chem* 297: 101182, 2021.
20. Peng Y, Xu Y, Zhang X, Deng S, Yuan Y, Luo X, Hossain MT, Zhu X, Du K, Hu F, *et al*: A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/ β -catenin signaling pathway to promote gastric cancer progression. *Mol Cancer* 20: 158, 2021.
21. Wu X, Xiao S, Zhang M, Yang L, Zhong J, Li B, Li F, Xia X, Li X, Zhou H, *et al*: A novel protein encoded by circular SMO RNA is essential for Hedgehog signaling activation and glioblastoma tumorigenicity. *Genome Biology* 22: 33, 2021.
22. Kos A, Dijkema R, Arnberg AC, van der Meide PH and Schellekens H: The hepatitis delta (delta) virus possesses a circular RNA. *Nature* 323: 558-560, 1986.
23. Perriman R and Ares M: Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo. *RNA* 4: 1047-1054, 1998.
24. Liu GM, Li Q, Zhang PF, Shen SL, Xie WX, Chen B, Wu J, Hu WJ, Huang XY and Peng BG: Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma. *Cell Death Dis* 9: 1132, 2018.
25. Zheng X, Chen L, Zhou Y, Wang Q, Zheng Z, Xu B, Wu C, Zhou Q, Hu W, Wu C and Jiang J: A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling. *Mol Cancer* 18: 47, 2019.
26. Pan Z, Cai J, Lin J, Zhou H, Peng J, Liang J, Xia L, Yin Q, Zou B, Zheng J, *et al*: A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer. *Mol Cancer* 19: 71, 2020.
27. Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade M, *et al*: Circ-ZNF609 Is a Circular RNA that can be translated and functions in myogenesis. *Mol Cell* 66: 22-37.e9, 2017.
28. Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, Hanan M, Wyler E, Perez-Hernandez D, Ramberger E, *et al*: Translation of CircRNAs. *Mol Cell* 66: 9-21, e7, 2017.
29. Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, Jin Y, Yang Y, Chen LL, Wang Y, *et al*: Extensive translation of circular RNAs driven by N⁶-methyladenosine. *Cell Res* 27: 626-641, 2017.
30. Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Márquez L, Marrugal Á, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, *et al*: FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy. *J Thorac Oncol* 14: 641-655, 2019.
31. Ye F, Gao G, Zou Y, Zheng S, Zhang L, Ou X, Xie X and Tang H: circFBXW7 inhibits malignant progression by sponging miR-197-3p and encoding a 185-aa protein in triple-negative breast cancer. *Mol Ther Nucleic Acids* 18: 88-98, 2019.
32. Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczynski A and Janz S: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. *Mol Cancer* 20: 84, 2021.
33. Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL and Yang L: Complementary sequence-mediated exon circularization. *Cell* 159: 134-147, 2014.
34. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, *et al*: Exon-intron circular RNAs regulate transcription in the nucleus. *Nat Struct Mol Biol* 22: 256-264, 2015.
35. Wang M, Yu F and Li PF: Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: Basic evidence and therapeutic implications. *Front Immunol* 14: 1268745, 2023.
36. Zhang L, Wang Y, Zhang Y, Zhao YF and Li PF: Pathogenic mechanisms and the potential clinical value of circFoxo3 in cancers. *Mol Ther-Nucl Acids* 23: 908-917, 2021.
37. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. *Nature* 495: 384-388, 2013.
38. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, *et al*: Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495: 333-338, 2013.
39. Liang ZX, Liu HS, Xiong L, Yang X, Wang FW, Zeng ZW, He XW, Wu XR and Lan P: A novel NF- κ B regulator encoded by circPCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation. *Mol Cancer* 20: 103, 2021.
40. Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, Zhu S, Yang L and Chen LL: Circular intronic long noncoding RNAs. *Mol Cell* 51: 792-806, 2013.
41. Sun G, Shen JF, Wei XF and Qi GX: Circular RNA Foxo3 relieves myocardial Ischemia/Reperfusion injury by suppressing autophagy via inhibiting HMGB1 by repressing KAT7 in myocardial infarction. *J Inflamm Res* 14: 6397-6407, 2021.
42. Zeng Y, Du WW, Wu Y, Yang Z, Awan FM, Li X, Yang W, Zhang C, Yang Q, Yee A, *et al*: A circular RNA binds to and activates AKT phosphorylation and nuclear localization reducing apoptosis and enhancing cardiac repair. *Theranostics* 7: 3842-3855, 2017.
43. Zhang Y, Jiang J, Zhang J, Shen H, Wang M, Guo Z, Zang X, Shi H, Gao J, Cai H, *et al*: CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability. *Mol Cancer* 20: 101, 2021.
44. Das S, Vera M, Gandin V, Singer RH and Tutucci E: Intracellular mRNA transport and localized translation. *Nat Rev Mol Cell Biol* 22: 483-504, 2021.
45. Prats AC, David F, Diallo LH, Roussel E, Tatin F, Garmy-Susini B and Lacazette E: Circular RNA, the key for translation. *Int J Mol Sci* 21: 8591, 2020.
46. Lei M, Zheng G, Ning Q, Zheng J and Dong D: Translation and functional roles of circular RNAs in human cancer. *Mol Cancer* 19: 30, 2020.
47. Choi JH, Wang W, Park D, Kim SH, Kim KT and Min KT: IRES-mediated translation of cofilin regulates axonal growth cone extension and turning. *EMBO J* 37: 2018.
48. Fan XJ, Yang Y, Chen CY and Wang ZF: Pervasive translation of circular RNAs driven by short IRES-like elements. *Nat Commun* 13: 3751, 2022.
49. Yang Y and Wang Z: IRES-mediated cap-independent translation, a path leading to hidden proteome. *J Mol Cell Biol* 11: 911-919, 2019.
50. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, Qian SB and Jaffrey SR: 5'UTR m(6)A promotes Cap-independent translation. *Cell* 163: 999-1010, 2015.
51. Zou Q, Xing P, Wei L and Liu B: Gene2vec: Gene subsequence embedding for prediction of mammalian N⁶-methyladenosine sites from mRNA. *Rna* 25: 205-218, 2019.
52. Gu Y, Wu X, Zhang J, Fang Y, Pan Y, Shu Y and Ma P: The evolving landscape of N⁶-methyladenosine modification in the tumor microenvironment. *Mol Ther* 29: 1703-1715, 2021.
53. Su T, Huang M, Liao J, Lin S, Yu P, Yang J, Cai Y, Zhu S, Xu L, Peng Z, *et al*: Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N⁶-Methyladenosine mRNA Methylation-Dependent mechanism. *Hepatology* 74: 1339-1356, 2021.

54. Glazar P, Papavasileiou P and Rajewsky N: circBase: A database for circular RNAs. *RNA* 20: 1666-1670, 2014.
55. Liu YC, Li JR, Sun CH, Andrews E, Chao RF, Lin FM, Weng SL, Hsu SD, Huang CC, Cheng C, *et al*: CircNet: A database of circular RNAs derived from transcriptome sequencing data. *Nucleic Acids Res* 44: D209-D215, 2016.
56. Chen XP, Han P, Zhou T, Guo XJ, Song XF and Li Y: circRNADb: A comprehensive database for human circular RNAs with protein-coding annotations. *Sci Rep* 6: 34985, 2016.
57. Meng XW, Chen Q, Zhang PJ and Chen M: CircPro: An integrated tool for the identification of circRNAs with protein-coding potential. *Bioinformatics* 33: 3314-3316, 2017.
58. Sun PS and Li GL: CircCode: A powerful tool for identifying circRNA coding ability. *Front Genetics* 10: 981, 2019.
59. Rombel IT, Sykes KF, Rayner S and Johnston SA: ORF-FINDER: A vector for high-throughput gene identification. *Gene* 282: 33-41, 2002.
60. Mokrejs M, Masek T, Vopalensky V, Hlubucek P, Delbos P and Pospisek M: IRESite-a tool for the examination of viral and cellular internal ribosome entry sites. *Nucleic Acids Res* 38 (Database Issue): D131-D136, 2010.
61. Wei LY, Chen HR and Su R: M6APred-EL: A sequence-based predictor for identifying N6-methyladenosine sites using ensemble learning. *Mol Ther Nucleic Acids* 12: 635-644, 2018.
62. Zhang YQ and Hamada M: DeepM6ASeq: Prediction and characterization of m6A-containing sequences using deep learning. *BMC Bioinformatics* 19 (Suppl 19): S524, 2018.
63. Zhao J, Li Y, Wang C, Zhang H, Zhang H, Jiang B, Guo X and Song X: IRESbase: A comprehensive database of experimentally validated internal ribosome entry sites. *Genomics Proteomics Bioinformatics* 18: 129-139, 2020.
64. Wu P, Mo YZ, Peng M, Tang T, Zhong Y, Deng X, Xiong F, Guo C, Wu X, Li Y, *et al*: Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA. *Mol Cancer* 19: 22, 2020.
65. Liu Y, Li Z, Zhang M, Zhou H, Wu X, Zhong J, Xiao F, Huang N, Yang X, Zeng R, *et al*: Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity. *Neuro Oncol* 23: 743-756, 2021.
66. Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, Song X, Han D, Wang X, Liu Y, *et al*: circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/ β -catenin pathway. *Mol Ther* 30: 415-430, 2022.
67. Liu L, Liu FB, Huang M, Xie K, Xie QS, Liu CH, Shen MJ and Huang Q: Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway. *Hepatobiliary Pancreat Dis Int* 18: 580-586, 2019.
68. Zhao HD, Zhou QJ and Li XT: Protein bait hypothesis: CircRNA-Encoded proteins competitively inhibit cognate functional isoforms. *Trends Genet* 37: 616-624, 2021.
69. Wang L, Zhou J, Zhang C, Chen R, Sun Q, Yang P, Peng C, Tan Y, Jin C, Wang T, *et al*: A novel tumour suppressor protein encoded by circMAPK14 inhibits progression and metastasis of colorectal cancer by competitively binding to MKK6. *Clin Transl Med* 11: e613, 2021.
70. Song J, Zheng J, Liu X, Dong W, Yang C, Wang D, Ruan X, Zhao Y, Liu L, Wang P, *et al*: A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5. *J Exp Clin Cancer Res* 41: 171, 2022.
71. McKinnon C, Nandhabalan M, Murray SA and Plaha P: Glioblastoma: Clinical presentation, diagnosis, and management. *BMJ* 374: n1560, 2021.
72. Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM and Breakefield XO: Multidimensional communication in the microenvirons of glioblastoma. *Nat Rev Neurol* 14: 482-495, 2018.
73. Caragher SP, Hall RR, Ahsan R and Ahmed AU: Monoamines in glioblastoma: Complex biology with therapeutic potential. *Neuro Oncol* 20: 1014-1025, 2018.
74. Marin-Bejar O, Marchese FP, Athie A, Sánchez Y, González J, Segura V, Huang L, Moreno I, Navarro A, Monzó M, *et al*: Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. *Genome Biol* 14: R104, 2013.
75. Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, Liu H, Xu J, Xiao F, Zhou H, *et al*: A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. *Nat Commun* 9: 4475, 2018.
76. Chen FX, Woodfin AR, Gardini A, Rickels RA, Marshall SA, Smith ER, Shiekhattar R and Shilatifard A: PAF1, a molecular regulator of promoter-proximal pausing by RNA Polymerase II. *Cell* 162: 1003-1015, 2015.
77. Unk I, Hajdu I, Fatyol K, Szakál B, Blastyák A, Bermudez V, Hurwitz J, Prakash L, Prakash S and Haracska L: Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. *Proc Natl Acad Sci USA* 103: 18107-18112, 2006.
78. Chen X, Sun N, Li R, Sang X, Li X, Zhao J, Han J, Yang J and Ikezoe T: Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis. *Int J Biol Sci* 17: 1263-1276, 2021.
79. Wang HJ, Hsieh YJ, Cheng WC, Lin CP, Lin YS, Yang SF, Chen CC, Izumiya Y, Yu JS, Kung HJ and Wang WC: JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1 α -mediated glucose metabolism. *Proc Natl Acad Sci USA* 111: 279-284, 2014.
80. Chin YR, Yuan X, Balk SP and Toker A: PTEN-Deficient tumors depend on AKT2 for maintenance and survival. *Cancer Discov* 4: 942-955, 2014.
81. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST and Li WP: Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development. *Mol Cancer* 16: 100, 2017.
82. Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, Huang N, Yang X, Xiao F, Liu D, *et al*: A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. *Mol Cancer* 18: 131, 2019.
83. Furnari FB, Cloughesy TF, Cavenee WK and Mischel PS: Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. *Nat Rev Cancer* 15: 302-310, 2015.
84. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB and Weller M: Advances in the molecular genetics of Gliomas-Implications for classification and therapy. *Nat Rev Clin Oncol* 14: 434-452, 2017.
85. Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, Zhong J, Zhao Z, Zhao K, Liu D, *et al*: Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. *Nat Cell Biol* 23: 278-291, 2021.
86. Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, *et al*: Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: New therapeutic opportunities. *Nat Med* 19: 1518-1523, 2013.
87. Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, *et al*: Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothed inhibition. *Cancer Cell* 25: 393-405, 2014.
88. Xie J: Hedgehog signaling pathway: Development of antagonists for cancer therapy. *Curr Oncol Rep* 10: 107-113, 2008.
89. Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol* 13: 674-690, 2016.
90. Li J, Ma M, Yang X, Zhang M, Luo J, Zhou H, Huang N, Xiao F, Lai B, Lv W and Zhang N: Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. *Mol Cancer* 19: 142, 2020.
91. Du Y, Zhang JY, Gong LP, Feng ZY, Wang D, Pan YH, Sun LP, Wen JY, Chen GF, Liang J, *et al*: Hypoxia-induced ebv-circLMP2A promotes angiogenesis in EBV-associated gastric carcinoma through the KHSRP/VHL/HIF1 α /VEGFA pathway. *Cancer Lett* 526: 259-272, 2022.
92. Ji L, Jiang B, Jiang X, Charlat O, Chen A, Mickanin C, Bauer A, Xu W, Yan X and Cong F: The SIAHE3 ubiquitin ligases promote Wnt/ β -catenin signaling through mediating Wnt-induced Axin degradation. *Genes Dev* 31: 904-915, 2017.
93. Futterer A, de Celis J, Navajas R, Almonacid L, Gutiérrez J, Talavera-Gutiérrez A, Pacios-Bras C, Bernascone I, Martín-Belmonte F and Martínez-A C: DIDO as a switchboard that regulates Self-Renewal and differentiation in embryonic stem cells. *Stem Cell Rep* 8: 1062-1075, 2017.
94. Kang DH, Lee DJ, Lee S, Lee SY, Jun Y, Kim Y, Kim Y, Lee JS, Lee DK, Lee S, *et al*: Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells. *Nat Commun* 8: 40, 2017.

95. Park YH, Kim SU, Kwon TH, Kim JM, Song IS, Shin HJ, Lee BK, Bang DH, Lee SJ, Lee DS, *et al*: Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway. *Oncogene* 35: 3503-3513, 2016.
96. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. *Lancet Oncol* 6: 322-327, 2005.
97. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018.
98. Yin F, Dong J, Kang LI and Liu X: Hippo-YAP signaling in digestive system tumors. *Am J Cancer Res* 11: 2495-2507, 2021.
99. Cai C, Rajaram M, Zhou X, Liu Q, Marchica J, Li J and Powers RS *et al*: Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. *Cell Cycle* 11: 1773-1781, 2012.
100. Liu HW, Bi JM, Dong W, Yang M, Shi J, Jiang N, Lin T and Huang J: Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis. *Mol Cancer* 17: 161, 2018.
101. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, *et al*: Loss of FBP1 by Snail-Mediated repression provides metabolic advantages in Basal-like breast cancer. *Cancer Cell* 23: 316-331, 2013.
102. Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG and Nebreda AR: Dual function of p38 α MAPK in colon cancer: Suppression of colitis-associated tumor initiation but requirement for cancer cell survival. *Cancer Cell* 25: 484-500, 2014.
103. Luo JL, Maeda S, Hsu LC, Yagita H and Karin M: Inhibition of NF-kappa B in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression. *Cancer Cell* 6: 297-305, 2004.
104. Clemons NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, Hague A, Paraskeva C and Williams AC: BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappa B activity. *Carcinogenesis* 29: 849-857, 2008.
105. Hodgson A, Wier EM, Fu K, Sun X, Yu H, Zheng W, Sham HP, Johnson K, Bailey S, Vallance BA and Wan F: Metalloprotease NleC suppresses host NF- κ B/inflammatory responses by cleaving p65 and interfering with the p65/RPS3 interaction. *PLoS Pathog* 11: e1004705, 2015.
106. Kim TS, Jang CY, Kim HD, Lee JY, Ahn BY and Kim J: Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation. *Mol Biol Cell* 17: 824-833, 2006.
107. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-E386, 2015.
108. Wang T, Liu Z, She Y, Deng J, Zhong Y, Zhao M, Li S, Xie D, Sun X, Hu X and Chen C: A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. *Cancer Lett* 520: 321-331, 2021.
109. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science* 275: 90-94, 1997.
110. Duan JL, Chen W, Xie JJ, Zhang ML, Nie RC, Liang H, Mei J, Han K, Xiang ZC, Wang FW, *et al*: A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. *Mol Cancer* 21: 93, 2022.
111. Liang WC, Wong CW, Liang PP, Shi M, Cao Y, Rao ST, Tsui SK, Waye MM, Zhang Q, Fu WM and Zhang JF: Translation of the circular RNA circ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. *Genome Biol* 20: 84, 2019.
112. Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG and Johnson JM: Metformin as a therapeutic target in endometrial cancers. *Front Oncol* 8: 341, 2018.
113. Kewley RJ, Whitelaw ML and Chapman-Smith A: The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. *Int J Biochem Cell Biol* 36: 189-204, 2004.
114. Pawlyn C and Morgan GJ: Evolutionary biology of high-risk multiple myeloma. *Nat Rev Cancer* 17: 543-556, 2017.
115. de Bussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, *et al*: Kinome expression profiling to target new therapeutic avenues in multiple myeloma. *Haematologica* 105: 784-795, 2020.
116. Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P and Grant S: Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. *Blood* 118: 5189-5200, 2011.
117. Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulosom R, D'Arrigo C, Ryder K, Menke A, Gress T and Downward J: CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. *Cancer Cell* 7: 521-532, 2005.
118. Yang F, Hu A, Guo Y, Wang J, Li D, Wang X, Jin S, Yuan B, Cai S, Zhou Y, *et al*: p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation. *Mol Cancer* 20: 123, 2021.
119. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin* 69: 363-385, 2019.
120. Hu X, Wu D, He X, Zhao H, He Z, Lin J, Wang K, Wang W, Pan Z, Lin H and Wang M: circGSK3 β promotes metastasis in esophageal squamous cell carcinoma by augmenting β -catenin signaling. *Mol Cancer* 18: 160, 2019.
121. Li CJ, Li DG, Liu EJ and Jiang GZ: Circ8199 encodes a protein that inhibits the activity of OGT by JAK2-STAT3 pathway in esophageal squamous cell carcinoma. *Am J Cancer Res* 13: 1107-1117, 2023.
122. Lyu YC, Tan BH, Li L, Liang R, Lei K, Wang K, Wu D, Lin H and Wang M: A novel protein encoded by circUBE4B promotes progression of esophageal squamous cell carcinoma by augmenting MAPK/ERK signaling. *Cell Death Dis* 14: 346, 2023.
123. De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. *Expert Opin Ther Tar* 16 (Suppl 2): S17-S27, 2012.
124. Liu Y, Li XG, Zhou XH, Wang JX and Ao X: FADD as a key molecular player in cancer progression. *Mol Med* 28: 132, 2022.
125. Liu Y, Wang Y, Li X, Jia Y, Wang J and Ao X: FOXO3a in cancer drug resistance. *Cancer Lett* 540: 215724, 2022.
126. Litke JL and Jaffrey SR: Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. *Nat Biotechnol* 37: 667-675, 2019.
127. Qu L, Yi ZY, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, *et al*: Circular RNA vaccines against SARS-CoV-2 and emerging variants. *Cell* 185: 1728-1744, 2022.

